Burnaby, British Columbia – March 11, 2024 – Qu Biologics Inc., a clinical stage biopharmaceutical company developing Site Specific Immunomodulators […]
Read More >
Qu Biologics Receives Accelerating Clinical Trial (ACT) Funding for PERIOP-06 Clinical Trial
Burnaby, British Columbia — Nov. 14, 2023 — Qu Biologics Inc., a clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a […]
Read More >
Qu Biologics and Karolinska Institute Initiate Important New Collaboration to Validate Molecular Mechanisms of Qu Biologics’ First-in-Class Immunotherapy Platform
Burnaby, British Columbia – December 14, 2022 – Qu Biologics Inc., a clinical stage biopharmaceutical company developing Site Specific Immunomodulators […]
Read More >
Qu Biologics to Receive Additional Funding to Support Innovative New Treatment to Restore Innate Immune Function in the Elderly
Burnaby, British Columbia – October 17, 2022 – Qu Biologics Inc., a clinical stage biopharmaceutical company developing Site Specific Immunomodulators […]
Read More >
Qu Biologics to Launch Phase 2B Clinical Trial to Assess Reduction of Postoperative Immune Suppression and Disease Progression in Patients with Late-Stage Colorectal Cancer
Burnaby, British Columbia – September 26, 2022 – Qu Biologics Inc., a clinical stage biopharmaceutical company developing Site Specific Immunomodulators […]
Read More >